This study aimed to identify a novel prognostic signature derived from an EGFR Tyrosine kinase inhibitors (TKI‐resistant) macrophage subpopulation and to evaluate its clinical and therapeutic relevance in HCC. The gene discussed is EGFR; the disease is hepatocellular carcinoma.